Geographic Atrophy

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, wa first-in-class mitochondria-targeted investigational therapeutic.

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease.

This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.

The company also reported a positive outcome of an analysis of masked data from its ongoing MAGNIFY Phase 2 trial for zervimesine in adults with GA.

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

The approval follows a refiling after the FDA issued a Complete Response Letter due to language on the amended label.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections

Among these eyes, 18.9% of eyes developed nAMD within 36 months.

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.

The potential gene therapy candidate is being evaluated for geographic atrophy.

The trial is evaluating GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.

A global survey explores the impact of geographic atrophy (GA) on quality of life, revealing similar challenges for individuals with unilateral and bilateral GA.

Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products including BRIMOCHOL PF for presbyopia and therapies for cataracts and geographic atrophy.

The annual meeting brought announcements and insights from companies in the retina care space.

The organization will provide resources for spreading awareness and educating patients and care givers.

Patients treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate.

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.